Investor Webinar Briefing (NASDAQ: RCEL, ASX: AVH)

Appointed as Chief Executive Officer of AVITA Medical in June 2017 after serving on the Board since February 2013, Dr. Perry brings extensive experience across the global pharmaceutical value chain for healthcare products spanning diverse therapeutic areas, including substantial expertise in cell therapies and cell-based gene therapies. In his career, he has been materially involved in the successful development and commercial launch of more than 30 prescription products, 14 of which achieved blockbuster status.

Prior to joining AVITA Medical, Dr. Perry’s leadership positions included Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit from 2014-2017; Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp. from 2012-2014.

With additional positions held as Global Head of R&D at Baxter Healthcare; President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc.; Vice President of Regulatory Affairs at Sandoz Pharmaceuticals Corporation; Director of Regulatory Affairs at Schering-Plough Corporation; and Venture Partner with Bay City Capital, LLC, Dr. Perry brings successful global management, guidance and forward direction to AVITA Medical. Since 2011, Dr. Perry has served as a Director with Arrowhead Pharmaceutical expanding his reach in influential medical growth.

Mr. Holder is a seasoned executive with more than 25 years of experience serving in senior financial, executive management and board roles with leading companies in the medtech, biotech, and pharma industries. Most recently, he served as Chief Financial Officer with ImmuneCyte, Inc., a global clinical stage biopharmaceutical company with innovative cell and gene immune-oncology therapeutics. At ImmuneCyte, Inc., Mr. Holder led preparations for a major IPO or SPAC transaction and was responsible for the development of financial team and infrastructure, M&A, and external audits.

Prior to that, Mr. Holder served as CEO and Portfolio Manager at Carolina Longevity Institute, LLC, a global investment company focused on medtech and life sciences investments, and initially CFO and later Chairman and CEO at Organ Transport Systems, Inc., a medical device company, where he built the company from early stage through multiple financing rounds as well as research, regulatory, and commercial launch activities. Prior to that, Mr. Holder was CFO of one public and two private medtech, healthcare and pharma-related companies. Mr. Holder has also served as an executive with the Sam Walton Family private equity fund and as a principal in the Corporate Development Group of AMR Corporation, a Fortune 500 company.

Mr. Holder holds a Master of Business Administration in Finance and Corporate Strategy from the Wharton School of Business at the University of Pennsylvania, a Bachelor of Science in Business Administration from the Kenan-Flagler Business School at the University of North Carolina, and previously obtained his CPA.

An accomplished global marketing and strategy leader whose proficiency at long-term planning has led to numerous successful product launches across the U.S, Europe and Asia Pacific, Mrs. Liberto brings more than 15 years of multifaceted global commercial experience developing, launching, managing, and optimizing healthcare portfolios with products that span therapeutic and aesthetic indications for international organizations including Allergan and Johnson & Johnson.

In her career, Mrs. Liberto has successfully launched more than a dozen products across diverse geographical markets. She has proven success in rapidly identifying business opportunities and formulating corresponding portfolio and brand strategies which drive revenue and global market share growth.

Erin holds an International MBA with a concentration in Global Marketing from Thunderbird School of Global Management in Arizona and a Bachelor of Commerce from McMaster University in Canada.

With more than 25 years of experience in medical device design, development, clinical research and medical affairs, Mr. Quick joined AVITA Medical in 2010 and is the Chief Technology Officer. Mr. Quick has held leadership positions in the development of diagnostic instrumentation and active implantable therapeutics, including most recently with Boston Scientific Neuromodulation / Advanced Bionics where he led U.S. investigational device and post-market clinical research in the cochlear implant business.

Mr. Quick holds Bachelor of Science and Master of Science degrees in Biomedical Engineering from Boston University.

Ms. McGee brings more than 25 years of biopharmaceutical and life sciences experience to AVITA Medical, most recently serving as President of CnA Consulting Group, which focuses on providing specialized consulting services to the life sciences industry. Prior to CnA Consulting, Ms. McGee was the Vice President of West Coast Operations at Shire Pharmaceuticals Regenerative Medicine Division, formerly Advanced BioHealing, where she was a part of the leadership team responsible for manufacturing operations, strategic planning, capital expansion, and real estate. At Advanced BioHealing, Ms. McGee served as the Senior Vice President of Operations and General Manager, with responsibility for the company’s manufacturing operations in La Jolla, CA. She has also held senior Operations leadership roles at Smith and Nephew and Advanced Tissue Sciences. She earned her Bachelor of Science in Chemistry and Mathematics from University College Galway Ireland, and holds a Master’s degree in Business and Management from Webster University.